Deep Vein Thrombosis (DVT)
19
5
6
12
Key Insights
Highlights
Success Rate
92% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 17/100
5.3%
1 terminated out of 19 trials
92.3%
+5.8% vs benchmark
26%
5 trials in Phase 3/4
42%
5 of 12 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 12 completed trials
Clinical Trials (19)
Cleaner Long-tErm Assessment Registry - Venous Insights and Efficacy With eXtended Tracking
Effectiveness and Cost-effectiveness of VTE Prevention Strategies in Gynecological Surgery
Study of Risk Factors and Prediction of Blood Clots After Lung Cancer Surgery
Progressive Gait Training After First-time Deep Venous Thrombosis: Clinical Effectiveness and Involved Mecanisms (The DVT-Cph RCT)
Nursing-Led Deep Vein Thrombosis Prevention in Neurosurgery
COMPARISON OF WARFARIN AND RIVAROXABAN IN THE TREATMENT OF LOWER LIMB DEEP VENOUS THROMBOSIS
Improving Emergency Department Testing for Deep Vein Thrombosis
To Compare and Evaluate the Oral Bioavailability of Edoxaban 60 mg Film Coated Tablet With That of Lixiana® 60 mg Filmtabletten (Film Coated Tablet) (Edoxaban) in Healthy, Adult, Human Subjects Under Fasting Conditions
Hokusai Study in Pediatric Patients With Confirmed Venous Thromboembolism (VTE)
Bemiparin as a Thromboprophylaxis After Gynaecological Surgeries
VTEval Project - Prospective Cohort Studies to Evaluate and Improve Diagnostics, Management Strategies and Risk Stratification in VTE
Lovenox 30 mg Twice Daily (BID) Versus 40 mg Once Daily (QD)
Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer
Osteopathic Treatment and Deep Vein Thrombosis (DVT)
Treatment of Venous Thromboembolism (VTE) With Either Rivaroxaban or Current Standard of Care Therapy
Evaluation of Soluble Fibrin in Thrombosis Exclusion
Below Knee DVT Study
Cancer Venous Thromboembolism (VTE)
Comparative Investigation of Low Molecular Weight (LMW) Heparin/Edoxaban Tosylate (DU176b) Versus (LMW) Heparin/Warfarin in the Treatment of Symptomatic Deep-Vein Blood Clots and/or Lung Blood Clots. (The Edoxaban Hokusai-VTE Study).